Jordan Carlson, OD
Optometrist · Seneca, SCNPI 1518606391
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.9% of the total across 101 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Biotissue Holdings Inc. at 24.7% of the total. 2025 is the largest year on record at $2,488, 8.2 times the $305 reported in 2022. Among optometrist clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 101 payments — averaging $55.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$1K
- Alcon$770
- Bausch & Lomb Americas Inc.$762
- Sun Pharmaceutical Industries Inc.$419
- Oyster Point Pharma, Inc.$396
- Amgen$311
- plus $2K from 11 others
What the payments were for
- Travel & lodging$3937%
- Food & beverage$5,16892%
- Entertainment$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 15 | $1,388 |
| Alcon | 11 | $770 |
| Bausch & Lomb Americas Inc. | 22 | $762 |
| Sun Pharmaceutical Industries Inc. | 4 | $419 |
| Oyster Point Pharma, Inc. | 12 | $396 |
| Amgen(2 entities) | 7 | $311 |
| Dompe US, Inc. | 4 | $287 |
| Sight Sciences, Inc. | 2 | $245 |
| Tarsus Pharmaceuticals, Inc. | 5 | $218 |
| Coopervision Inc. | 3 | $209 |
| LKC Technologies, Inc. | 2 | $191 |
| Rayner Intraocular Lenses Limited | 3 | $159 |
| AbbVie | 4 | $92 |
| Harrow Eye, LLC | 4 | $84 |
| Optos, Inc. | 1 | $60 |
| Glaukos Corporation | 1 | $18 |
| Tearlab Corp | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$471
- CEQUA$353
- Oxervate$245
- TEPEZZA$239
- MIEBO$220
- TYRVAYA$214
- OMNI(R) SURGICAL SYSTEM (US)$154
- Clareon$142
- Precision 1$136
- RayOne EMV$124
- RayOne Spheric$124
- RayOne Aspheric$124
- VYZULTA$118
- XDEMVY$112
- Hydrus Microstent$103
- TOTAL30$101
- XIIDRA$100
- INFUSE$100
How this compares
$5,621 in reported general payments places this provider in the 90th percentile of 653 optometrist providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 36 | $46,237 |
| MieboPerfluorohexyloctane/Pf | 24 | $19,456 |
| Cyclosporine | 25 | $12,703 |
| CequaCyclosporine | 14 | $9,379 |
| LumiganBimatoprost | 18 | $4,867 |
| Loteprednol Etabonate | 18 | $2,850 |
| Prednisolone Acetate | 54 | $1,454 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 162 | $1,445 |
| Latanoprost | 88 | $1,127 |
| Doxycycline Hyclate | 38 | $507 |
| MoxifloxacinMoxifloxacin Hcl | 22 | $432 |
| ValacyclovirValacyclovir Hcl | 15 | $329 |
| Timolol Maleate | 25 | $311 |
| ErythromycinErythromycin Base | 36 | $304 |
| Cephalexin | 15 | $82 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $92 | $51,10554 claims |
| Bausch & Lomb Americas Inc.Miebo | $762 | $19,45624 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $419 | $9,37914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 653 optometrist providers in South Carolina.
Other optometrist in Seneca
- Thomas WeshefskyMyrtle Beach$77K
- Richard BedellCharleston$55K
- Patrick VollmerColumbia$49K
- William ColemanEasley$22K
- Furman SmithMt Pleasant$21K
- Jennifer ZolmanCharleston$21K
- Steven AndreasenGreenville$19K
- Bridget WhaleyGreenville$18K
- Scott OliverRock Hill$16K
- Michael CriswellMount Pleasant$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.